Undisclosed ocular disorder-related RNA

Undisclosed ocular disorder-related RNA is a placeholder designation used in the biotechnology and pharmaceutical industries to refer to proprietary RNA molecules—such as messenger RNA (mRNA), pre-mRNA, or non-coding RNA—that are being investigated as therapeutic targets for eye diseases. This term is frequently employed in pipeline reports and clinical trial registries by companies specializing in RNA-targeted therapies, such as Ionis Pharmaceuticals, ProQR Therapeutics, and Alnylam Pharmaceuticals, to protect intellectual property during early-stage development. These targets are typically implicated in the pathogenesis of conditions like inherited retinal diseases, age-related macular degeneration, or glaucoma. Therapeutic interventions for these undisclosed targets generally utilize advanced modalities such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), or RNA editing technologies to modulate gene expression or correct genetic mutations. Examples of drug candidates associated with such undisclosed targets include ISIS-GSK4-LRx and AX-1501, which are designed to treat specific but unnamed ocular pathologies. Once a program reaches a significant clinical milestone or a patent is published, the specific identity of the RNA target is typically disclosed to the scientific community.

Other names

Undisclosed ocular targetUndisclosed ophthalmic target

Antisense oligonucleotide, RNA interference, RNA editing